{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T23:49:21Z","timestamp":1771890561842,"version":"3.50.1"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T00:00:00Z","timestamp":1744070400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>Hemiplegic migraine (HM) is a rare subtype of migraine with aura characterized by transient unilateral motor weakness during attacks. Although monoclonal antibodies (mABs) targeting the calcitonin gene-related peptide (CGRP) pathway have shown efficacy in migraine prevention, their role in HM remains largely unexplored, since these patients are generally excluded from randomized clinical trials aimed at developing migraine preventive drugs. We present a case of a middle-aged woman with chronic migraine and recurrent hemiplegic episodes treated with fremanezumab. After 11\u202fmonths of monthly 225\u202fmg subcutaneous fremanezumab injections, the patient experienced a substantial reduction in monthly headache days, aura episodes, and symptom severity, without safety concerns. This case adds to the emerging evidence supporting CGRP mABs as a potential therapeutic option for HM. Further research is needed to elucidate their precise mechanism and determine their efficacy in broader HM populations.<\/jats:p>","DOI":"10.3389\/fneur.2025.1579203","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T06:10:45Z","timestamp":1744092645000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy of anti-calcitonin gene-related peptide monoclonal antibodies in hemiplegic migraine: a case report and review of literature"],"prefix":"10.3389","volume":"16","author":[{"given":"M\u00e1t\u00e9","family":"H\u00e9ja","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u00e1szl\u00f3","family":"Ol\u00e1h","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,8]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s10194-020-01208-0","article-title":"Lifting the burden: the global campaign against headache. Migraine remains second among the world's causes of disability, and first among young women: findings from GBD2019","volume":"21","author":"Steiner","year":"2020","journal-title":"J Headache Pain"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","article-title":"Headache Classification Committee of the International Headache Society (IHS) The international classification of headache disorders, 3rd edition","volume":"38","year":"2018","journal-title":"Cephalalgia"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.jocn.2021.09.025","article-title":"Ischemic stroke mimics: A comprehensive review","volume":"93","author":"Pohl","year":"2021","journal-title":"J Clin Neurosci"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1177\/03331024231159366","article-title":"Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: A systematic review and network meta-analysis of phase 3 randomised controlled trials","volume":"43","author":"Haghdoost","year":"2023","journal-title":"Cephalalgia"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1177\/03331024241269735","article-title":"International headache society global practice recommendations for preventive pharmacological treatment of migraine","volume":"44","author":"Puledda","year":"2024","journal-title":"Cephalalgia"},{"key":"ref6","article-title":"Hemiplegic migraine","volume-title":"StatPearls","author":"Kumar","year":"2024"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"e57790","DOI":"10.7759\/cureus.57790","article-title":"A rare case of sporadic hemiplegic migraine mimicking stroke: A diagnostic challenge solved by comprehensive history taking","volume":"16","author":"Kaushal","year":"2024","journal-title":"Cureus"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"e306","DOI":"10.1161\/STROKEAHA.122.041369","article-title":"Hemiplegic migraine as a stroke mimic: imaging and electroencephalography findings","volume":"54","author":"Ryan","year":"2023","journal-title":"Stroke"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/S1474-4422(11)70048-5","article-title":"Sporadic and familial hemiplegic migraine: pathophysiological mechanisms, clinical characteristics, diagnosis, and management","volume":"10","author":"Russell","year":"2011","journal-title":"Lancet Neurol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.4103\/0972-2327.99993","article-title":"Pathophysiology of migraine","volume":"15","author":"Goadsby","year":"2012","journal-title":"Ann Indian Acad Neurol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1136\/jnnp-2020-322850","article-title":"Diagnostic and therapeutic aspects of hemiplegic migraine","volume":"91","author":"Di Stefano","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1177\/0333102418779544","article-title":"Discovery of CGRP in relation to migraine","volume":"39","author":"Edvinsson","year":"2019","journal-title":"Cephalalgia"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"18985","DOI":"10.1073\/pnas.1215435109","article-title":"Critical role of calcitonin gene-related peptide receptors in cortical spreading depression","volume":"109","author":"Tozzi","year":"2012","journal-title":"Proc Natl Acad Sci"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"6001","DOI":"10.1523\/JNEUROSCI.0232-19.2019","article-title":"CSD-induced arterial dilatation and plasma protein extravasation are unaffected by Fremanezumab: implications for CGRP's role in migraine with Aura","volume":"39","author":"Schain","year":"2019","journal-title":"J Neurosci"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1212\/01.wnl.0000325482","article-title":"Calcitonin gene-related peptide does not cause the familial hemiplegic migraine phenotype","volume":"71","author":"Hansen","year":"2008","journal-title":"Neurology"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"54453","DOI":"10.1111\/j.1526-4610.2011.01861.x","article-title":"Calcitonin gene-related peptide does not cause migraine attacks in patients with familial hemiplegic migraine","volume":"51","author":"Hansen","year":"2011","journal-title":"Headache"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1111\/head.14591","article-title":"Treatment of hemiplegic migraine with anticalcitonin gene-related peptide monoclonal antibodies: A case series in a tertiary-care headache center","volume":"63","author":"Danno","year":"2023","journal-title":"Headache"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"5535","DOI":"10.1007\/s10072-024-07665-8","article-title":"Sporadic hemiplegic migraine with novel missense mutation in the SCN1A gene and positive response to anti-CGRP antibody: a case report","volume":"45","author":"D'Apolito","year":"2024","journal-title":"Neurol Sci"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"5535","DOI":"10.1007\/s10072-024-07980-0","article-title":"A case of sporadic hemiplegic migraine treated with eptinezumab: should we consider anti-CGRP antibodies for selected patients?","volume":"45","author":"Antenucci","year":"2025","journal-title":"Neurol Sci"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/bcp.12618","article-title":"CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment","volume":"80","author":"Edvinsson","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"e77146","DOI":"10.7554\/eLife.77146","article-title":"Migraine monoclonal antibodies against CGRP change brain activity depending on ligand or receptor target\u2014an fMRI study","volume":"11","author":"Basedau","year":"2022","journal-title":"eLife"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"e2794","DOI":"10.1212\/WNL.0000000000010740","article-title":"Central effects of erenumab in migraine patients: an event-related functional imaging study","volume":"95","author":"Ziegeler","year":"2020","journal-title":"Neurology"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1007\/s10072-023-07241-6","article-title":"Are anti-calcitonin gene-related peptide monoclonal antibodies effective in treating migraine aura? A pilot prospective observational cohort study","volume":"45","author":"Braca","year":"2024","journal-title":"Neurol Sci"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1097\/j.pain.0000000000001791","article-title":"Fremanezumab and its isotype slow propagation rate and shorten cortical recovery period but do not prevent occurrence of cortical spreading depression in rats with compromised blood-brain barrier","volume":"161","author":"Melo-Carrillo","year":"2020","journal-title":"Pain"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1579203\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T06:10:56Z","timestamp":1744092656000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1579203\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,8]]},"references-count":24,"alternative-id":["10.3389\/fneur.2025.1579203"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2025.1579203","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,8]]},"article-number":"1579203"}}